RBC Capital Downgrades BioCryst Pharma to Sector Perform, Lowers Price Target to $11

Benzinga Newsdesk www.benzinga.com Negative 93.8%

Neg 93.8% Neu 0% Pos 0%

RBC Capital analyst Brian Abrahams downgrades BioCryst Pharma (NASDAQ:BCRX) from Outperform to Sector Perform and lowers the price target from $13 to $11.